Australia’s 150-Day Priority Review Pathway Set For July Kick-Off
Executive Summary
Drug sponsors who plan to use Australia’s forthcoming priority review pathway anytime soon can start notifying the Therapeutic Goods Administration of their intention to do so now.
You may also be interested in...
Australian Provisional Approval Pathway To Get Tough On Sponsors Upfront
Plans by Australia’s Therapeutic Goods Administration to develop a provision approval pathway for drugs have moved up a gear.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Outlook Turns To Marketing Strategy After Scoring EU First For Ophthalmic Bevacizumab
Outlook Therapeutics’ intravitreally injected Lytenava has won the thumbs up from the European Medicines Agency. The company is assessing both direct commercialization of the product and partnering in Europe on a country-by-country basis.